Clinical characteristics and current management of hepatitis B and C in China

Table 2 Laboratory assessments and anti-hepatitis B virus treatments administered to patients with hepatitis B virus infection, and the responses to treatment n (%)

	HBV(n = 2562)	HBV and HCV(n = 42)
Laboratory assessments:
HBsAg positive1	2195/2207 (99.5)	32/35 (91.4)
HBeAg positive1	971/2137 (45.4)	5/34 (14.7)
HBeAb positive1	1056/2092 (50.4)	26/32 (81.3)
HBV DNA positive1	1278/2286 (55.9)	313/38 (34.2)
ALT abnormal	944 (36.8)	19 (45.2)
AST abnormal	740 (28.9)	16 (38.1)
AFP abnormal	142/866 (16.3)	4/22 (18.2)
Received antiviral treatment	1490 (58.2)	22 (52.4)
Latest antiviral therapies	(n = 1490)	(n = 22)
Interferon (IFN)	109 (7.3)	2 (9.1)
PEG-IFN	99 (6.6)	14 (63.6)
Lamivudine	467 (31.3)	4 (18.2)
Telbivudine	238 (16.0)	1 (4.5)
Adefovir dipivoxil	691 (46.4)	4 (18.2)
Entecavir	230 (15.4)	2 (9.1)
Duration of completed treatment, months, median (IQR)	(n = 1309)	(n = 21)
	11.2 (0-187.8)	7.8 (0.6-69.6)
Responses to treatment	(n = 801)	(n = 12)
Virological response2	645 (80.5)	11 (91.7)
Biochemical response3	465 (58.1)	5 (41.7)
Serological response4	105 (13.1)	2 (16.7)
Treatment status5
Sustained response6	5/38 (13.2)	0
Virological breakthrough	20/801 (2.5)	0

¹Patients with records from the most recent tests;

²Includes HBV DNA not detected or below lower limit of detection, or HBV DNA decreased by ≥ log10 IU/mL vs baseline;

³ALT and AST returned to normal;

⁴Includes HBeAg negative or seroconversion and HBsAg negative or seroconversion;

⁵Excludes patients in whom treatment was terminated and patients not yet evaluated due to ongoing treatment;

⁶Sustained response: patients who achieved and had a sustained response for at least 6 mo after completing therapy. AFP: α-Fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBeAb: Hepatitis B e antibody; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; IQR: Interquartile range; NA: Nucleos(t)ide analog; PEG-IFN: Pegylated interferon.